Nanogels As Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics

Overview

Journal Front Bioeng Biotechnol

Date 2022 Aug 5

PMID 35928954

Authors

Yunhan Zhang

Zhulin Zou

Shuang Liu

Shengjie Miao

Haiyan Liu

Affiliations

Soon will be listed here.

Abstract

Nanogels have come out as a great potential drug delivery platform due to its prominently high colloidal stability, high drug loading, core-shell structure, good permeation property and can be responsive to environmental stimuli. Such nanoscopic drug carriers have more excellent abilities over conventional nanomaterials for permeating to brain parenchyma and . Nanogel-based system can be nanoengineered to bypass physiological barriers via non-invasive treatment, rendering it a most suitable platform for the management of neurological conditions such as neurodegenerative disorders, brain tumors, epilepsy and ischemic stroke, etc. Therapeutics of central nervous system (CNS) diseases have shown marked limited site-specific delivery of CNS by the poor access of various drugs into the brain, due to the presences of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Hence, the availability of therapeutics delivery strategies is considered as one of the most major challenges facing the treatment of CNS diseases. The primary objective of this review is to elaborate the newer advances of nanogel for CNS drugs delivery, discuss the early preclinical success in the field of nanogel technology and highlight different insights on its potential neurotoxicity.

Citing Articles

A Revolutionary Approach for Combating Efflux Transporter-mediated Resistant Epilepsy: Advanced Drug Delivery Systems.

Tonk M, Singh I, Sharma R, Chauhan S Curr Pharm Des. 2024; 31(2):95-106.

PMID: 39279709 DOI: 10.2174/0113816128332345240823111524.

Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases.

Ozceylan O, Sezgin-Bayindir Z ACS Omega. 2024; 9(33):35223-35242.

PMID: 39184484 PMC: 11340000. DOI: 10.1021/acsomega.4c01774.

Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective.

Gupta J, Sharma G Drug Deliv Transl Res. 2024; 15(2):455-482.

PMID: 39103593 DOI: 10.1007/s13346-024-01684-w.

Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.

Song Q, Li J, Li T, Li H Adv Sci (Weinh). 2024; 11(38):e2403473.

PMID: 39101248 PMC: 11481234. DOI: 10.1002/advs.202403473.

Chitosan-Tricarbocyanine-Based Nanogels Were Able to Cross the Blood-Brain Barrier Showing Its Potential as a Targeted Site Delivery Agent.

Rivera Lopez E, Samaniego Lopez C, Spagnuolo C, Berardino B, Alaimo A, Perez O Pharmaceutics. 2024; 16(7).

PMID: 39065661 PMC: 11280413. DOI: 10.3390/pharmaceutics16070964.

References

Khan O, Chaudary N . The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults. Drug Des Devel Ther. 2020; 14:2287-2294. PMC: 7293904. DOI: 10.2147/DDDT.S146111. View

Logan S, Arzua T, Canfield S, Seminary E, Sison S, Ebert A . Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. Compr Physiol. 2019; 9(2):565-611. PMC: 6705133. DOI: 10.1002/cphy.c180025. View

Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

Fassas A, Anagnostopoulos A . The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005; 46(6):795-802. DOI: 10.1080/10428190500052438. View

Hawkins B, Davis T . The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57(2):173-85. DOI: 10.1124/pr.57.2.4. View

Pardridge W . Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2004; 3(2):90-105, 51. DOI: 10.1124/mi.3.2.90. View

He Q, Liu J, Liang J, Liu X, Li W, Liu Z . Towards Improvements for Penetrating the Blood-Brain Barrier-Recent Progress from a Material and Pharmaceutical Perspective. Cells. 2018; 7(4). PMC: 5946101. DOI: 10.3390/cells7040024. View

Alyautdin R, Khalin I, Nafeeza M, Haron M, Kuznetsov D . Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014; 9:795-811. PMC: 3926460. DOI: 10.2147/IJN.S52236. View

Zhou T, Xiao C, Fan J, Chen S, Shen J, Wu W . A nanogel of on-site tunable pH-response for efficient anticancer drug delivery. Acta Biomater. 2012; 9(1):4546-57. DOI: 10.1016/j.actbio.2012.08.017. View

10.

Amoli-Diva M, Sadighi-Bonabi R, Pourghazi K . Switchable on/off drug release from gold nanoparticles-grafted dual light- and temperature-responsive hydrogel for controlled drug delivery. Mater Sci Eng C Mater Biol Appl. 2017; 76:242-248. DOI: 10.1016/j.msec.2017.03.038. View

11.

Furtado D, Bjornmalm M, Ayton S, Bush A, Kempe K, Caruso F . Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018; 30(46):e1801362. DOI: 10.1002/adma.201801362. View

12.

Wohlfart S, Gelperina S, Kreuter J . Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2011; 161(2):264-73. DOI: 10.1016/j.jconrel.2011.08.017. View

13.

Li D, Mastaglia F, Fletcher S, Wilton S . Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era. Med Res Rev. 2020; 40(6):2650-2681. PMC: 7589267. DOI: 10.1002/med.21718. View

14.

Soni V, Jain A, Khare P, Gulbake A, Jain S . Potential approaches for drug delivery to the brain: past, present, and future. Crit Rev Ther Drug Carrier Syst. 2010; 27(3):187-236. DOI: 10.1615/critrevtherdrugcarriersyst.v27.i3.10. View

15.

Patel V, Chavda V, Shah J . Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems. Curr Neuropharmacol. 2020; 19(5):693-710. PMC: 8573747. DOI: 10.2174/1570159X18666200807143526. View

16.

Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Shiri Varnamkhasti B, Saboury A . Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Biomed Pharmacother. 2018; 109:1100-1111. DOI: 10.1016/j.biopha.2018.10.167. View

17.

Kleindorfer D, Khatri P, Katzan I . Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. 2005; 65(11):1844. View

18.

Shringarpure M, Gharat S, Momin M, Omri A . Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery. Expert Opin Drug Deliv. 2020; 18(2):169-185. DOI: 10.1080/17425247.2021.1823965. View

19.

Lee G, Dallas S, Hong M, Bendayan R . Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev. 2001; 53(4):569-96. View

20.

Francischi J, Pereira L, Castro M . Cyclosporin inhibits hyperalgesia and edema in arthritic rats: role of the central nervous system. Braz J Med Biol Res. 1997; 30(1):101-11. DOI: 10.1590/s0100-879x1997000100016. View